Bone marrow impairment during early [177Lu]PSMA-617 radioligand therapy: Haematotoxicity or tumour progression?
Sign Up to like & getrecommendations! Published in 2022 at "EJNMMI Research"
DOI: 10.1186/s13550-022-00891-1
Abstract: Background The recent phase III VISION-trial confirms the treatment efficacy of radioligand therapy with [ 177 Lu]PSMA-617 (PSMA-RLT) in metastatic castration-resistant prostate cancer (mCRPC). In PSMA-RLT, the relatively low absorbed bone marrow dose allows for… read more here.
Keywords: bone marrow; psma rlt; marrow impairment; psma ... See more keywords